|
Miraculins Inc.,
a biotechnology company engaged in the discovery and development of biomarkers
and diagnostics for select cancers, is pleased to announce that it has retained
the services of CHF Investor Relations (Cavalcanti Hume Funfer Inc.), Canada's
longest established and one of its most respected IR firms, based in Toronto
and Calgary.
Read More
|
|
Miraculins Inc.,
a biotechnology company engaged in the discovery and development of biomarkers
and diagnostics for select cancers, is pleased to announce that the Company
was today named to the 2005 TSX Venture 50(TM), the first ever ranking of Canada's
top emerging public companies listed on TSX Venture Exchange.
Read More
|
|
Miraculins Inc.,
a biotechnology company engaged in the discovery and development of biomarkers
and diagnostics for select cancers, is pleased to announce that the Company
will be presenting data from its ongoing prostate cancer diagnostic project
at the International Conference on Molecular Targets and Cancer Therapeutics,
co-organized by the American Association for Cancer Research (AACR), the National
Cancer Institute (NCI) and the European Organization for Research and Treatment
of Cancer (EORTC) at the Pennsylvania Conference Center in Philadelphia, from
November 14-18.
Read More
|
|
Miraculins Inc.,
a biotechnology company engaged in the discovery and development of biomarkers
and diagnostics for select cancers, is pleased to announce that the Company
will be providing a corporate update at BioContact in Quebec City, Quebec.
Read More
|
|
Miraculins
Inc., a biotechnology company engaged in the discovery and
development of products for select cancers, is pleased to announce that
Dr. Vincent Lenaerts has been appointed President of the Company
effective immediately.
Read More
|
|
|